Global Health: Science and Practice (GHSP)
June 2016 | Volume 4 | Issue 2
http://www.ghspjournal.org/content/current

.

EDITORIALS
A Convenient Truth: Cost of Medications Need Not Be a Barrier to Hepatitis B Treatment
Drugs that are inexpensive to manufacture and simple to administer greatly expand the potential to help tens of millions of people who need treatment for chronic hepatitis B virus (HBV) infection. Key program implementation challenges include identifying who would benefit from antiviral medication and ensuring long-term and consistent treatment to people who feel well. The best opportunities are where health systems are advanced enough to effectively address these challenges and in settings where HIV service platforms can be leveraged. Research, innovation, and collaboration are critical to implement services most efficiently and to realize economies of scale to drive down costs of health care services, drugs, and diagnostics.
Matthew Barnhart
Glob Health Sci Pract 2016;4(2):186-190. First published online June 16, 2016. http://dx.doi.org/10.9745/GHSP-D-16-00128

.

COMMENTARIES
Investing in Family Planning: Key to Achieving the Sustainable Development Goals
Voluntary family planning brings transformational benefits to women, families, communities, and countries. Investing in family planning is a development “best buy” that can accelerate achievement across the 5 Sustainable Development Goal themes of People, Planet, Prosperity, Peace, and Partnership.
Ellen Starbird, Maureen Norton, Rachel Marcus
Glob Health Sci Pract 2016;4(2):191-210. First published online June 9, 2016. http://dx.doi.org/10.9745/GHSP-D-15-00374

.

mHealth for Tuberculosis Treatment Adherence: A Framework to Guide Ethical Planning, Implementation, and Evaluation
Promising mHealth approaches for TB treatment adherence include:
:: Video observation
:: Patient- or device-facilitated indirect monitoring
:: Direct monitoring through embedded sensors or metabolite testing
To mitigate ethical concerns, our framework considers accuracy of monitoring technologies, stigmatization and intrusiveness of the technologies, use of incentives, and the balance of individual and public good.
Michael J DiStefano, Harald Schmidt
Glob Health Sci Pract 2016;4(2):211-221. http://dx.doi.org/10.9745/GHSP-D-16-00018

.